When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Anti-amyloid drugs - Wikipedia

   en.wikipedia.org/wiki/Anti-amyloid_drugs

   Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [10] It was developed by Biogen and Eisai. [11] Aducanumab is given via intravenous infusion. [5] Aducanumab was ...

3. Lecanemab - Wikipedia

   en.wikipedia.org/wiki/Lecanemab

   Lecanemab may cause amyloid-related imaging abnormalities (ARIA). ARIA is often asymptomatic, but serious and life-threatening events rarely may occur.ARIA most commonly presents as temporary swelling of the brain that usually resolves over time and may be accompanied by small spots of bleeding in or on the surface of the brain, though some people may have symptoms such as headache, confusion ...

4. Donepezil - Wikipedia

   en.wikipedia.org/wiki/Donepezil

   Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [3] [4] [8] It appears to result in a small benefit in mental function and ability to function. [9]

5. Aducanumab - Wikipedia

   en.wikipedia.org/wiki/Aducanumab

   Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.

6. US FDA staff raise no major concerns about Eli Lilly ... - AOL

   www.aol.com/news/us-fda-panel-vote-data...

   An FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients ...

7. American Journal of Alzheimer's Disease & Other Dementias

   en.wikipedia.org/wiki/American_Journal_of...

   The American Journal of Alzheimer's Disease & Other Dementias is a peer-reviewed academic journal that publishes papers in the field of neurology. The journal's editor is Carol F. Lippa, MD (Drexel University College of Medicine). It has been in publication since 1986 and is currently published by SAGE Publications.